Littleton, CO, September 11, 2011 --(PR.com
)-- Novus Biologicals announced today a new NODAL antibody (catalog number NBP1-71686) for the study of cancer, angiogenesis and stem cells. This NODAL antibody was made using SDIX Genomic AntibodiesTM (GATTM).
This NODAL Antibody (NBP1-71686) serves as an excellent tool for studying stem cell signaling and as a marker for cancer research.
NODAL is an important TGF-beta family protein in cellular differentiation. While constitutively expressed in many developing tissues, NODAL is problematically associated with the differentiation and development of many cancers. The expression of NODAL is regulated by a Notch signaling pathway, which when disrupted contributes to the aggressive behavior of metastatic cancer cells, particularly in melanoma. The abundance of NODAL expression in melanoma can help determine the stage of cancer and metastatic type/progression when tested in IHC.
SDIX GAT uses sophisticated bioinformatics and immunization strategies to produce high-quality antibodies that specifically bind to that region of the protein in its naturally folded form. The ability of any antibody to recognize a protein’s naturally folded state has the potential to expand an antibody’s utility to high-value applications like sandwich immunoassay, ChIP, and flow cytometry. Learn more about GAT by reading the GAT FAQ or by downloading the GAT White Paper.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.
About SDIX (www.sdix.com)
SDIX is a biotechnology company with a core expertise at creating better antigens, better antibodies and better assays for the pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX has been a leading immuno-solutions Company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.
In the life science market, SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs, and provide antibodies and assays for the diagnosis of disease. In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost effective results.